SRZN: Ascending Triangle detected on 30 Mar 2026

Surrozen is forming an ascending triangle pattern as the stock trades near its resistance level of 29.46, with analyst price targets raised to 36 from 32 at H.C. Wainwright on March 24, 2026. The pattern shows solid structure (15/15) and breakout potential (11.7/13), though volume is moderate at 10.2/12 with current volume 78,465 shares tracking 0.86 relative to the 20-day average. The pattern quality score of 75.9 overall suggests a well-formed setup with 62.82% win probability. Price consolidation between 23.72 support and 29.46 resistance reflects institutional accumulation following recent rallies—the stock has gained 14.91% over one week and 26.2% in three months.

Surrozen reported Q4 2025 results on March 23, 2026, announcing a planned IND submission for lead candidate SZN-8141 in H2 2026 and a 5 million dollar milestone payment from Boehringer Ingelheim for SZN-413. Cash position strengthened to 89.2 million dollars as of December 31, 2025, up from 34.6 million a year earlier. H.C. Wainwright raised its price target to 36 dollars from 32 dollars on March 24. The average 12-month price target is 36.67 dollars with three analysts recommending buying. This bullish analyst action combined with the imminent IND submission catalyzes the current ascending triangle formation—the company is transitioning from cash burn funded by partnerships to clinical validation of its Wnt pathway ophthalmology program.

A breakout above the 29.46 resistance would target 30.68 (conservative measured move), with volume confirmation required to validate a sustained move. Historical ascending triangle data indicates buyers controlling price at higher levels, suggesting breakout success at the 62.82% win probability. Invalidation occurs at support 23.72—below this level, the pattern fails and suggests broader weakness. Success depends on volume surge above the 91,005-share 20-day average; current below-average volume (0.86 ratio) means momentum breakout will require institutional follow-through as IND submission timing approaches in H2 2026.

The balance sheet shows a 187.8 million dollar stockholders' deficit with tranche and warrant liabilities totaling over 270 million dollars, a notable capital-structure overhang. Surrozen filed a 200 million dollar mixed securities shelf on March 23, 2026, signaling likely dilutive financing ahead. Weiss Ratings maintains a sell rating on the stock. RSI of 63.33 approaches overbought territory and combined with sector/market bearish regimes (-0.56 and -0.5 respectively) suggests limited momentum tailwind. IND approval success and clinical trial outcomes remain binary risks inherent to clinical-stage biotech; a failed IND or adverse Phase 1 data would crater the stock. Low beta (0.32) provides some downside cushion, but the capital structure and shelf filing create concrete dilution risk that could pressure shares post-breakout.